IL-17 receptor A antigen binding proteins

1. A method of treating COPD, comprising administering to a patient having COPD a pharmaceutical composition comprising an human monoclonal antibody selected from the group:

a. an isolated antibody, comprising a light chain variable domain sequence comprising SEQ ID NO:40 and a heavy chain variable domain sequence comprising SEQ ID NO:14; and

b. an isolated antibody, comprising a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, a light chain CDR3 comprising SEQ ID NO:226, a heavy chain CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID NO:147 and a heavy chain CDR3 comprising SEQ ID NO:148,

wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to said IL-17 receptor A.

2. The method of claim 1 , further comprising administering to said patient a second treatment comprising a pharmaceutical composition,

wherein said second treatment is administered prior to, concurrent with, or subsequent to administration of said pharmaceutical composition comprising said antibody and

wherein said antibody is:

a. an IgG1 antibody;

b. an IgG2 antibody;

c. an IgG3 antibody; or

d. an IgG4 antibody.

3. The method of claim 1 , wherein said antibody is:

a. an antigen-binding antibody fragment;

b. a single chain antibody;

c. a diabody;

d. a triabody;

e. a tetrabody;

f. a Fab fragment;

g. a F(ab′)2 fragment;

h. an IgD antibody;

i. an IgE antibody;

j. an IgM antibody;

k. an IgG1 antibody;

l. an IgG2 antibody;

m. an IgG3 antibody; or

n. an IgG4 antibody.

4. The method of claim 1 , wherein said antibody is:

a. an IgG1 antibody; or

b. an IgG2 antibody.

5. The method of claim 1 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable diluent.

6. The method of claim 1 , wherein said antibody is a human IgG2 monoclonal antibody.

7. The method of claim 1 , wherein the antibody comprises a light chain sequence encoded by a polynucleotide comprising nucleotides 84-741 of SEQ ID NO:428 and a heavy chain sequence encoded by a polynucleotide comprising SEQ ID NO:426, wherein said antibody is produced from a Chinese Hamster Ovary Cell (CHO cell), and wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to said IL-17 receptor A.

8. The method of claim 7 , further comprising administering to said patient a second treatment comprising a pharmaceutical composition,

wherein said second treatment is administered prior to, concurrent with, or subsequent to administration of said composition comprising said antibody.

9. The method of claim 7 , wherein said composition pharmaceutical composition further comprises a pharmaceutically acceptable diluent.

10. The method of claim 7 , wherein said antibody is a human IgG2 monoclonal antibody.

11. The method of claim 7 , wherein said antibody is glycosylated.

12. The method of claim 7 , wherein said composition pharmaceutical composition further comprises a pharmaceutically acceptable diluent.

13. A method of treating COPD, comprising administering to a patient having COPD a pharmaceutical composition comprising an isolated human monoclonal antibody comprising a light chain CDR1 comprising SEQ ID NO:224, a light chain CDR2 comprising SEQ ID NO:225, a light chain CDR3 comprising SEQ ID NO:226, a heavy chain CDR1 comprising SEQ ID NO:146, a heavy chain CDR2 comprising SEQ ID NO:147 and a heavy chain CDR3 comprising SEQ ID NO:148, wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to said IL-17 receptor A.

14. The method of claim 13 , further comprising administering to previously presented aid patient a second treatment comprising a pharmaceutical composition,

wherein said second treatment is administered prior to, concurrent with, or subsequent to administration of said composition comprising said antibody.

15. The method of claim 13 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable diluent.

16. The method of claim 13 , wherein said antibody is:

a. an IgG1 antibody;

b. an IgG2 antibody;

c. an IgG3 antibody; or

d. an IgG4 antibody.

17. The method of claim 13 , wherein said antibody is a human IgG2 monoclonal antibody.

18. A method of treating COPD comprising administering to a patient having COPD a composition comprising an isolated antibody comprising a light chain variable domain sequence comprising SEQ ID NO:40 and a heavy chain variable domain sequence comprising SEQ ID NO:14, wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to said IL-17 receptor A.

19. The method of claim 18 , further comprising administering to said patient a second treatment comprising a pharmaceutical composition

wherein said second treatment is administered prior to, concurrent with, or subsequent to administration of said composition comprising said antibody.

20. The method of claim 18 , wherein said composition comprises a pharmaceutically acceptable diluent.

21. The method of claim 18 wherein said antibody is:

a. a human antibody;

b. a humanized antibody;

c. a chimeric antibody;

d. a monoclonal antibody;

e. an antigen-binding antibody fragment;

f. a single chain antibody;

g. a Fab fragment;

h. a F(ab′)2 fragment;

i. an IgG1 antibody; or

j. an IgG2 antibody.

22. The method of claim 18 , wherein said antibody is a human antibody.

23. The method of claim 18 , wherein said antibody is a monoclonal antibody.

24. The method of claim 18 , wherein said antibody is a human monoclonal antibody.

25. The method of claim 18 , wherein said antibody is a human IgG2 monoclonal antibody.

26. The method of claim 18 , wherein said composition is a pharmaceutical composition.

27. The method of claim 26 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable diluent.

28. The method of claim 18 , wherein the antibody comprises an isolated antibody comprising a light chain sequence comprising amino acids 21-234 of SEQ ID NO: 429 and a heavy chain sequence comprising SEQ ID NO: 427, wherein said antibody specifically binds to human IL-17 receptor A and inhibits the binding of IL-17A to said IL-17 receptor A.

29. The method of claim 28 , further comprising administering to said patient a second treatment comprising a pharmaceutical composition

wherein said second treatment is administered prior to, concurrent with, or subsequent to administration of said composition comprising said antibody.

30. The method of claim 28 , wherein said antibody is:

a. an IgG1 antibody

b. an IgG2 antibody; or

g. an IgG2 antibody.

31. The method of claim 30 , wherein said antibody is a human IgG2 monoclonal antibody.

32. The method of claim 28 , wherein said pharmaceutical composition further comprises a pharmaceutically acceptable diluent.